

Declaration Ref No: DC22-0065

CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

We,

Atlas Medical GmbH

Head office: Ludwig-Erhard-Ring 3 Blankenfelde-Mahlow, Germany. Tel: +49 - 33708 – 3550 30 Email: info@atlas-medical.com

Manufacturing Site: Sahab Free Zone Area, P. O. Box 204, Amman 11512, Jordan.

Tel.: +962 6 4026468
Fax: +962 6 4022588
Email: info@atlas-medical.com

Declare our responsibility that the following product:

See Attached list

- Comply with all essential requirements (AnnexI) of the IVD Directive 98/79/EC. This
 compliance has been properly documented and covers the items listed in Annex I of the IVD
 Directive.
- This product is produced under Atlas quality system (ISO13485:2016) issued by GMED: Certificate No.: 36655 rev 1

Expiry Date: October 8 th.2023

Comply with the essential requirements of following standards (EN 18113-1, -2,-4:2011, EN ISO 15223:2016, EN ISO 23640:2015, EN ISO 14971:2019, ISO 2859/1:1999, EN ISO 13612:2002, EN ISO 13641:2002.

And

Intended for In-Vitro Professional use only.

Manufacturer
Atlas Medical
Ludwig-Erhard-Ring 3
Blankenfelde-Mahlow, Germany.



Atlas	Issue date	Date of review	Management approval	MRXDO10F.10
Medical	May.2022	21.05.2022		08.02.2011

CE Declaration of Conformity

According to Annex III of the IVD Directive 98/79/EC

Item code	Product Description	
8.00.01.0.0100	Atlas CRP Latex Kit with Buffer (100 Tests)	
8.00.05.0.0100	Atlas RF Latex kit with Buffer(100 Tests)	
8.00.11.0.0050	Atlas SLE Latex kit (50 Tests)	
8.00.11.0.0100	Atlas SLE Latex kit (100 Tests)	
8.00.12.0.0100	Atlas Staphylococcus Latex Kit (100 Tests)	
8.00.17.0.0050	Atlas D-Dimer Latex Kit (50 Tests)	
8.00.19.3.0100	Atlas TPHA Kit (100 Tests)	
8.00.19.3.0200	Atlas TPHA Kit (200 Tests)	
8.00.20.3.2500	Atlas VDRL Kit, 5ml+55ml buffer	
8.04.38.0.0020	Atlas Fecal Occult Blood Test (FOB) Test Cassette , 20	
	Tests/Box	
8.04.85.0.0050	Atlas Fecal Occult Blood Test (FOB) Test Strip, 50 Tests/Box	
8.04.109.0.0020	Atlas Procalcitonin test (PCT), 20 Tests/Box	
8.16.78.0.0025	Atlas Calprotectin Test Cassette , 25 Tests/Box	
8.04.45.0.0001	Atlas Troponin I Test Cassette, Bulk	
8.04.45.0.0020	Atlas Troponin I Test Cassette , 20 Tests/Box.	
8.04.45.0.0030	Atlas Troponin I Test Cassette , 30 Tests/Box.	
8.04.46.0.0001	Atlas Myoglobin Test Cassette, Bulk	
8.04.46.0.0020	Atlas Myoglobin Test Cassette , 20 Tests/Box.	
8.04.46.0.0030	Atlas Myoglobin Test Cassette , 30 Tests/Box.	
8.04.47.0.0001	Atlas CK-MB Test Cassette , Bulk.	
8.04.47.0.0020	Atlas CK-MB Test Cassette , 20 Tests/Box.	
8.04.47.0.0030	Atlas CK-MB Test Cassette , 30 Tests/Box.	
8.04.48.0.0001	Atlas Cardiac Triple Tests Cassette (Troponin I, CK-MB,	
	Myoglobin), Bulk.	
8.04.48.0.0020	Atlas Cardiac Triple Tests Cassette (Troponin I, CK-MB,	
	Myoglobin), 20 Tests/Box.	
8.04.48.0.0030	Atlas Cardiac Triple Tests Cassette (Troponin I, CK-MB,	
0.4.4.0.4.0006	Myoglobin), 30 Tests/Box.	
8.14.19.1.0096	Helicobacter pylori Antigen ELISA, 96 Tests.	
8.51.00.0.0096	25-OH VITAMIN D Elisa Kit, 96 Tests.	
8.57.00.0.0096	Vitamin B12 Elisa Kit, 96 Tests	





Declaration Ref No: DC21-0193

CE Declaration of Conformity

We, Atlas Medical GmbH

Head office: Ludwig-Erhard-Ring 3 15827 Blankenefelde-Mahlow Germany

Tel: +49(0)33708355030 Email: <u>info@atlas-medical.com</u>

Middle East Site: Sahab Industrial Zone Area, King Abdullah II Industrial City

Amman 11512, Jordan Tel.: +962 6 4026468 Fax: +962 6 4022588

Email: info@atlas-medical.com

Declare our responsibility that the following product:

Product Code	Product Name	Class	GMDN code
8.00.18.0.0005	RPR Carbon Antigen Reagent, 5 ml/vial	General-IVD	32450
8.00.18.2.1000	RPR Carbon Antigen 1000ml/bottle	General-IVD	32450
8.00.18.0.0050	RPR Carbon Antigen Kit, 50 Tests	General-IVD	32450
8.00.18.1.0050	RPR Carbon Antigen Kit, 50 Tests, White Glass Slide.	General-IVD	32450
8.00.18.2.0500	RPR Carbon Antigen Kit, 500 Tests (2ml latex, 2x0.5 ml control) Without card.	General-IVD	32450
8.00.18.3.0500	RPR Carbon Antigen Kit, 500 Tests (10ml latex, 2x0.5 ml control) Without card, stirring sticks.	General-IVD	32450
8.00.18.0.0100	RPR Carbon Antigen Kit, 100 Tests (2ml latex, 2x0.5 ml control)	General-IVD	32450
8.00.18.2.0100	RPR Carbon Antigen Kit, 100 Tests (2ml latex, 2x0.5 ml control +White Glass slide stirring sticks)	General-IVD	32450
8.00.18.0.0025	RPR Carbon Antigen Kit, 25 Tests (0.5ml latex, 2x0.5 ml control)	General-IVD	32450
8.00.18.0.0150	RPR Carbon Antigen Kit, 150 Tests	General-IVD	32450
8.00.18.0.0200	RPR Carbon Antigen Kit, 200 Tests	General-IVD	32450
	RPR Carbon Antigen Kit, 250 Tests	General-IVD	32450

Atlas	First issue date	Date of review	Management approvate Produc	MRXDO10F.10	
Medical	September.2021	06.09.2021	Amen	08.02.2011	
			Amoni Al-Hobartal		
			RA Manay		





Declaration Ref No: DC21-0193

8.00.18.0.0500	RPR Carbon Antigen Kit,500 Tests	General-IVD	32450
8.00.18.0.1000	RPR Carbon Antigen Kit, 1000 Tests	General-IVD	32450
8.00.18.4.0500	RPR Carbon Antigen Kit,500 Tests (3x3.4ml reagent,2x1 controls)	General-IVD	32450
8.00.18.5.0500	RPR Carbon Antigen Kit, 500 Tests, (3x3.4ml reagent,2x1 controls)	General-IVD	32450
8.00.18.8.0500	RPR Carbon Antigen 500 Test (10ml reagent) without Control's.	General-IVD	32450
8.00.18.9.0050	RPR Carbon Antigen Kit, (5x10ml Reagent,2x2ml Control), white glass Slide, Stirring Stick.	General-IVD	32450
8.33.04.0.0001	RPR Positive control	General-IVD	32450
8.33.04.1.0001	RPR Positive control ,Bulk	General-IVD	32450
8.33.04.0.0100	RPR Positive control(100ml/vial)	General-IVD	32450
8.33.04.0.0500	RPR Positive control(500ml/bottle)	General-IVD	32450
8.33.08.0.0001	RPR Negative control	General-IVD	32450

Is produced under Atlas quality system (ISO13485: 2016) supported by GMED certificate:

Certificate N⁰.: 36655 rev 1 Expiry Date: October 8 th.2023

and complies with the essential requirements of In Vitro Diagnostic Medical Devices Directive 98/79/EC Annex I

And

EN ISO 18113-1, -2 :2011, EN ISO 15223:2016 EN ISO 14971:2019, EN ISO 23640 :2015 , ISO 2859 :2017, EN 13612:2002, EN 13641:2002 , EN 13975:2003, ISO 13485:2016

And

Intended for In-Vitro Professional use only.

This Declaration includes the batches produced beyond this day according to the product Lot Log.

Manufacturer Atlas Medical GmbH Ludwig-Erhard-Ring 3 15827 Blankenefelde-Mahlow Germany.



First issue date	Date of review	Management approval	MRXDO10F.10
September.2021	06.09.2021	Anen	08.02.2011
		Armi Al-Habartel	





CERTIFICATCERTIFICATE OF REGISTRATION

N° 36655 rev.1

GMED certifie que le système de management de la qualité développé par

GMED certifies that the quality management system developed by

ATLAS MEDICAL GmbH Ludwig-Erhard-Ring 3 15827 Blankenfelde-Mahlow GERMANY

pour les activités

for the activities

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic in vitro .

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices.

réalisées sur le(s) site(s) de performed on the location(s) of

Voir addendum

See addendum

est conforme aux exigences des normes internationales complies with the requirements of the international standards

ISO 13485: 2016

Début de validité / Effective date October 9th, 2020 (included) Valable jusqu'au / Expiry date : October 8th, 2023 (included)

Etabli le / Issued on : October 8th, 2020

On be

On behalf of the President Béatrice LYS

Technical Director

DocuSigned by:

GMED N° 36655-1

Ce certificat est délivré selon les règles de certification GMED / This certificate is issued according to the rules of GMED certification

Renouvelle le certificat 36655-0

RECEITIFICATION DE SYSTEMES DE MANAGEMENT
A Loste des sites accrédit et et portée disponible su www.cofrac.fr

GMED •

GMED • Société par Actions Simplifiée au capital de 300 000 € • Organisme Notifié/Notified Body n° 0459 Siège social : 1, rue Gaston Boissier - 75015 Paris • Tél. : 01 40 43 37 00 • gmed.fr



Addendum au certificat n° 36655 rev. 1 page 1/1 Addendum of the certificate n° 36655 rev. 1 Dossier / File N°P601408

Ce certificat couvre les activités et les sites suivants :

This certificate covers the following activities and sites:

French version:

Conception et développement, fabrication et vente de dispositifs médicaux de diagnostic *in vitro* à usage professionnel et/ ou d'autodiagnostic, dans les domaines du groupage sanguin, de la microbiologie, de la biochimie, de la toxicologie, de l'oncologie, de la cardiologie, de l'histologie, de l'endocrinologie et des maladies infectieuses, dans les techniques d'Agglutination/ ELISA/ Tests rapides/ Colorimétrie/ Disques antibiotiques.

English version:

Design and Development, Manufacturing and Sales of in vitro diagnostic medical devices for professional use and/or for self-testing, in the field of Immunohematology, Microbiology, Biochemistry, Toxicology, Oncology, Cardiology, Histology, Endocrinology Biosensors and Infectious diseases, in techniques of Agglutination/ELISA/Rapid tests/Colorimetry/Antibiotic disks.

ATLAS MEDICAL GmbH Ludwig-Erhard-Ring 3 15827 Blankenfelde-Mahlow GERMANY

French version:

Siège social, responsable de la mise sur le marché

English version:

Headquarter, legal manufacturer

Sahab Industrial Zone Area King Abdullah II Industrial City Amman 11512 JORDAN

French version:

Conception, fabrication et contrôle final

English version:

Design, manufacture and final control

William James House Cowley Road, Cambridge, CB OWX United Kingdom

French version:

Contact réglementaire

English version:

Regulatory Administration

3 sites / 3 sites

Bratrice Lys

EF33BDA9BAA04A3...

On behalf of the President Béatrice LYS Technical Director



Date: 05/Jan/2023

STATEMENT

We, Atlas Medical having a registered office at Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany assign SRL Sanmedico having a registered office at A. Corobceanu Street 7A, apt.9, Chisinau MD-2012, Moldova, as authorized representative in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

On Behalf of Manufacturer:

General Manager

Haya Amawi

Signature

Atlas Medical GmbH

> 2Ludwig - Erhard Ring 3

15827 Blankenfelde - Mahlow Tel. (0049) 33708 - 355030

Atlas Medical: Ludwig-Erhard-Ring 3, 15827 Blankenfelde-Mahlow, Berlin, Germany, Tel:+4933708355030

Regulatory Office: William James House, Cowley Rd, Cambridge, CB4 0WX, United Kingdom Tel: +44 (0) 1223 858 910

Middle East Site: P.O Box 204, King Abdullah II Industrial Estate, Amman, 11512, Jordan Tel: +962 6 4026468





RPR SYPHILIS CARD TEST

IVD For In-Vitro diagnostic and professional use only



INTRODUCTION

Syphilis is a disease caused by infection with the spirochete Treponema pallidum. The infection is systemic and the disease is characterized by periods of latency. These features, together with the fact that T pallidum cannot be isolated in culture, mean that serologic techniques play a major role in the diagnosis and follow-up of treatment for syphilis.

Syphilis is categorized by an early primary infection in which patients may have non-specific symptoms, and potentially, genital lesions. Patients tested by serology during the primary phase may be negative for antibodies, especially if testing is performed during the first 1 to 2 weeks after symptom onset. As the disease progresses into the secondary phase. antibodies to T pallidum reach peak titers, and may persist indefinitely regardless of the disease state or prior therapy. Therefore, detection of antibodies to nontreponemal antigens, such as cardiolipin (a lipoidal antigen released by host cells damaged by T pallidum) may help to differentiate between active and past syphilis infection. Nontreponemal antibodies are detected by the rapid plasma reagin (RPR) assay, which is typically positive during current infection and negative following treatment or during late/latent forms of syphilis.

PRINCIPLE

RPR utilises carbon particles coated with cardiolipin antigen to detect reagin antibodies present in serum or plasma of syphilitic persons.

Specimens that contain reagin cause aggregation of the carbon particles which appear as dark clumps against a white background. The aggregation can be read macroscopically. Non-reactive samples typically appear as a smooth non-aggregated pattern which may form buttons in the centre of the test area.

MATERIALS PROVIDED

- RPR carbon antigen reagent: Contains less than 0.1% sodium azide.
- **Positive Control**: Contains less than 0.1% sodium azide.
- Negative control: Contains less than 0.1% sodium azide

- RPR test cards (Optional).
- Plastic sticks.
- Package insert.

NOTE: This package insert is also used for individually packed reagent.

MATERIALS NEEDED BUT NOT PROVIDED

- Rotator (100rpm).
- Timer.
- Pipettes.

SAMPLES

Fresh serum or plasma. The samples with presence of fibrin should be centrifuged before testing. Do not use highly hemolized or lipemic samples.

PRECAUTIONS

- For professional in vitro diagnostic use only. Do not use after expiration date.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Always use a fresh pipette tip for every test.
- Handle all negative and positive in the manner as patient specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
- The used test should be discarded according to local regulations.
- Components of different human origin have been tested and found to be negative for the presence of antibodies anti- HIV 1+2 and anti-HCV, as well as for HBsAg. However, the controls should be handled cautiously as potentially infectious.

STORAGE AND STABILITY

All components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8°C.

PROCEDURES

QUALITATIVE PROCEDURE

- Mix well the RPR reagent before use.
- 1. Bring the reagents and samples to room temperature.
- 2. Dispense **50 μL of each sample** into a separate circle on the card. Use a separate tip for each sample.
- 3. Dispense 1 drop of each of positive and negative controls into two additional circles.
- Gently shake the dispensing vial and slightly press to remove air bubbles from the needle and the drop obtained is correct.

- 5. Dispense 1 drop (17.5 µl) of RPR antigen to each circle next to the sample to be tested.
- 6. Place the card on a mechanical rotator and rotate at 100 r.p.m. for 8 minutes.
- 7. Observe macroscopically for agglutination within a minute after removing the card from the rotator.

SEMI-QUANTITATIVE PROCEDURE

- Mix well the RPR reagent before use.
- Make doubling dilutions from Undiluted to 1:16 normal saline.
- 2. Place $50 \,\mu l$ of each dilution in to a separate circle on the test card.
- 3. Spread each dilution evenly over the test circle.
- Continue as from Qualitative procedure.
 The titer of the sample is expressed as the final dilution which shows aggregation of the carbon particles.

PERFORMANCE CHARACTERISTICS

Sensitivity: 100%.
 Specificity: 100%.

INTERPRETATION OF TEST RESULTS

 Strong Reactive: Large clumps of carbon particles with a clear background.



2. Reactive: Large clumps of carbon particles somewhat more disperse than Strong Reactive pattern.



3. Weak Reactive: Small clumps of carbon particles with light grey background.



4. Trace Reactive: Slight clumping of carbon particles typically seen as a button of aggregates in the centre of the test circle or dispersed around the edge of the test circle.



5. Non-Reactive: Typically a smooth grey pattern or a button of non-aggregated carbon particles in the centre of the test circle.



REFERENCES

• Falcone V.H., Stout G.W. and Moore M.B. Jr., PHR 79: 491-495, 1964.



Ludwig-Erhard Ring 3 15827 Blankenfelde-Mahlow Germany

Tel: +49 - 33708 - 3550 30

Email: Info@atlas-medical.com Website: www.atlas-medical.com

PPI2074A01 Rev B (15.03.2021)

REF	Catalogue Number	1	Temperature limit
IVD	In Vitro diagnostic medical device	\triangle	Caution
\sum	Contains sufficient for <n> tests and Relative size</n>		Consult instructions for use (IFU)
LOT	Batch code		Manufacturer
Ī	Fragile, handle with care		Use-by date
Dia .	Manufacturer fax number	(8)	Do not use if package is damaged
	Manufacturer telephone number	E	Date of Manufacture
誉	Keep away from sunlight	Ť	Keep dry



Fecal Occult Blood Test Strip (Feces)

A rapid, one step test for the qualitative detection of human occult blood in feces.

IVD For In-Vitro diagnostic and professional use only



INTENDED USE

The FOB One Step Fecal Occult Blood Test Strip (Feces) is a rapid chromatographic immunoassay for the qualitative detection of human occult blood in feces.

INTRODUCTION

Most of diseases can cause hidden blood in the stool. In the early stages, gastrointestinal problems such as colon cancer, ulcers, polyps, colitis, diverticulitis, and fissures may not show any visible symptoms, only occult blood. Traditional guaiac-based method lacks sensitivity and specificity, and has diet-restriction prior to the testing.

The FOB One Step Fecal Occult Blood Test Strip (Feces) is a rapid test to qualitatively detect low levels of fecal occult blood in feces. The test uses double antibody sandwich assay to selectively detect as low as 50ng/mL of hemoglobin or 6µg hemoglobin/g feces. In addition, unlike the guaiac assays, the accuracy of the test is not affected by the diet of the patients.

PRINCIPLE

The FOB One Step Fecal Occult Blood Test Strip (Feces) is a qualitative, lateral flow immunoassay for the detection of human occult blood in feces. The membrane is precoated with anti-hemoglobin antibody on the test line region of the Strip. During testing, the specimen reacts with the particle coated with anti-hemoglobin antibody. The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-hemoglobin antibody on the membrane and

generate a colored line. The presence of this colored line in the test region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

MATERIALS

MATERIALS PROVIDED

- Test Strip(contains anti-hemoglobin antibody particles and anti-hemoglobin antibody coated on the membrane).
- Specimen collection tube with extraction buffer.
- Package insert.

MATERIALS NEEDED BUT NOT PROVIDED

- Specimen collection container.
- Timer.
- Pipette.

PRECAUTIONS

- For professional *in vitro* diagnostic use only. Do not use after expiration date.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the testing and follow the standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
- Humidity and temperature can adversely affect results.

STORAGE AND STABILITY

- The kit can be stored at room temperature or refrigerated (2-30°C).
- The test Strip is stable through the expiration date printed on the sealed pouch.

- The test Strip must remain in the sealed pouch until use.
- Do not freeze.
- Do not use beyond the expiration date.


PATIENT PREPARATION

- Specimen should not be collected during or within three days of a menstrual period, or if the patient suffers from bleeding hemmorhoids or blood in the urine.
- Alcohol, aspirin and other medications taken in excess may cause gastrointestinal irritation resulting in occult bleeding. Such substances should be discontinued at least 48 hours prior to testing.
- Dietary restrictions are not necessary.

PROCEDURE

- Allow the test strips and samples to reach room temperature (15-30°C) prior to testing. Do not open the package until ready to perform the assay.
- Using the applicator stick of the provided sample diluent vial, transfer a small portion (5mm diameter) of stool specimen into the sample diluent.
- 3. Shake gently in order to unstuck and facilitate the sample dispersion.
- 4. Hold the vial and break the tip off.
- 5. Dispense 10 drops (approximately 0.5 ml) of the sample extract in a test tube.
- Immerse the test strip in the liquid prepared in step 5. Do not exceed the line shown on the strip.
- 7. Read the result 5 minutes after the immersion of the strip. Do not read result after 10 minutes.

INTERPRETATION OF RESULTS (Please refer to the illustration below)



POSITIVE:*

Two distinct red lines appear. One line should be in the control region (C) and another line should be in the test region (T).

*NOTE:

The intensity of the red color in the test line region (T) will vary depending on the concentration of hemoglobin present in the specimen. Therefore, any shade in the test region indicates positive result.

NEGATIVE:

One red line appears in the control region (C). No apparent red or pink line appears in the test region (T).

INVALID:

Control line fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test Strip. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

EXPECTED VALUES

The FOB One Step Fecal Occult Blood Test Strip (Feces) has been compared with another leading commercial rapid test. The correlation between these two systems is 98%.

QUALITY CONTROL

 A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms

- sufficient specimen volume and correct procedural technique.
- Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATION

- The FOB One Step Fecal Occult Blood Test Strip (Feces) is for *in vitro* diagnostic use only.
- The FOB One Step Fecal Occult Blood Test Strip (Feces) will only indicate the presence of human hemoglobin in the specimen and the presence of blood in feces may be other than colorectal bleeding.
- As with all diagnostic tests, all results must be considered with other clinical information available to the physician.
- Other clinically available tests are required if questionable results are obtained.

PERFORMANCE CHARACTERISTICS

Sensitivity

The FOB One Step Fecal Occult Blood Test Strip (Feces) can detect the levels of human occult blood as low as 50 ng/mL hemoglobin or around 2µg hemoglobin/g feces.

Specificity

The FOB One Step Fecal Occult Blood Test Strip (Feces) is specific to human hemoglobin. Specimen containing the following substances at the standard concentration were tested on both positive and negative controls with no effect on test results.

Substances	Concentrations (Diluted with the extraction buffer)	
Bovine hemoglobin	1 mg/mL	
Chicken	1 mg/mL	
Pork hemoglobin	1 mg/mL	
Goat hemoglobin	1 mg/mL	
Horse hemoglobin	1 mg/mL	

Rabbit hemoglobin	1 mg/mL
Turkey hemoglobin	1 mg/mL

REFERENCES

- Simon J.B. Occult Blood Screening for Colorectal Carcinoma: A Critical Review, Gastroenterology, Vol. 1985; 88: 820.
- 2. Blebea J. and Ncpherson RA. *False-Positive Guaiac Testing With Iodine, Arch Pathol Lab Med,* 1985;109:437-40

ATLAS MEDICAL

William James House, Cowley Rd, Cambridge, CB4 4WX, UK

Tel: ++44 (0) 1223 858 910

Fax: ++44 (0) 1223 858 524

PPI589A01

Rev C (23.04.2015)

REF	Product Reference No.	IVD	For in-vitro
	Reference No.		diagnostic use.
À	Caution.		Store at 2 - 30°C.
(i	Read product insert before use.	Σ	Number of tests in the pack.
LOT	Lot (batch) number.	•••	Manufacturer.
2<	Expiry date.		Manufacturer telephone number.
	Manufacturer fax number.	_	